INTELLIA THERAPEUTICS, INC. Deferred Revenue Recognized
INTELLIA THERAPEUTICS, INC. (NTLA) reported Deferred Revenue Recognized of $7.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-06
- INTELLIA THERAPEUTICS, INC. contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was $6.66M, a 30.72% increase year-over-year.
- INTELLIA THERAPEUTICS, INC. contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was $5.09M, a 5.10% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. contract with customer, liability, revenue recognized for the quarter ending 2024-03-31 was $5.37M, a 54.32% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. contract with customer, liability, revenue recognized for the quarter ending 2023-03-31 was $11.75M, a 5.10% increase year-over-year.
- INTELLIA THERAPEUTICS, INC. contract with customer, liability, revenue recognized for fiscal 2025 was $29.68M, a 34.46% increase from fiscal 2024.
- INTELLIA THERAPEUTICS, INC. contract with customer, liability, revenue recognized for fiscal 2024 was $22.08M, a 5.91% decline from fiscal 2023.
- INTELLIA THERAPEUTICS, INC. contract with customer, liability, revenue recognized for fiscal 2023 was $23.46M, a 54.93% decline from fiscal 2022.
- INTELLIA THERAPEUTICS, INC. contract with customer, liability, revenue recognized for fiscal 2022 was $52.06M, a 130.93% increase from fiscal 2021.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.29M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $6.66M 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $29.68M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $15.45M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $10.24M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $5.09M 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | $22.08M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $16.23M 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $10.76M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | $5.37M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $23.46M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $31.08M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $23.27M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $11.75M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $52.06M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $38.21M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $24.44M 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | $11.18M 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $22.54M 10-K · filed 2024-02-22 | |||
| 2021-09-30 | $16.86M 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $11.18M 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $5.56M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $11.57M 10-K · filed 2023-02-23 | |||
| 2020-09-30 | $10.25M 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | $5.67M 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | $3.15M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $27.12M 10-K · filed 2021-02-26 | |||
| 2019-09-30 | $23.79M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $15.77M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $7.84M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $22.94M 10-K · filed 2020-02-27 | |||
| 2018-09-30 | $16.60M 10-Q · filed 2019-10-31 | |||
| 2018-06-30 | $11.01M 10-Q · filed 2019-08-01 | |||
| 2018-03-31 | $5.47M 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |